Cargando…

A nomogram for predicting the HER2 status of circulating tumor cells and survival analysis in HER2-negative breast cancer

BACKGROUND: In breast cancer patients with HER2-negative tumors (tHER2-), HER2-positive CTCs (cHER2+) were associated with promising efficacy of HER2-targeted therapy, but controversy has persisted over its prognostic effect. We developed a model including clinicopathologic parameters/blood test var...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Yuqin, Li, Liudan, Tian, Wenjing, Qiao, Zhen, Qin, Qi, Su, Liqian, Li, Peiqiu, Chen, Weirong, Zhao, Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811813/ https://www.ncbi.nlm.nih.gov/pubmed/36620609 http://dx.doi.org/10.3389/fonc.2022.943800

Ejemplares similares

Clinical-radiomics nomogram for identifying HER2 status in patients with breast cancer: A multicenter study
por: Fang, Caiyun, et al.
Publicado: (2022)

A Novel Prognostic Nomogram for Predicting Survival of Hormone Receptor-Positive and HER2 Negative Advanced Breast Cancer Among the Han-Population
por: Zhu, Yimin, et al.
Publicado: (2022)

Development and validation of novel immune-inflammation-based clinical predictive nomograms in HER2-negative advanced gastric cancer
por: Yang, Yan, et al.
Publicado: (2023)

Preclinical HER-2 Vaccines: From Rodent to Human HER-2
por: Lollini, Pier-Luigi, et al.
Publicado: (2013)

In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China
por: Li, Yiqun, et al.
Publicado: (2022)

Are There More HER2 FISH in the Sea? An Institution’s Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry
por: Suydam, Camille, et al.
Publicado: (2023)

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
por: Fehm, Tanja, et al.
Publicado: (2007)

Tumor-Infiltrating Cytotoxic T Cells and Tumor-Associated Macrophages Correlate With the Outcomes of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
por: Yang, Yuqin, et al.
Publicado: (2021)

New Advances in Targeted Therapy of HER2-Negative Breast Cancer
por: An, Junsha, et al.
Publicado: (2022)

HER2 somatic mutations are associated with poor survival in HER2‐negative breast cancers
por: Wang, Tonghui, et al.
Publicado: (2017)

Review of the status of neoadjuvant therapy in HER2-positive breast cancer
por: Dowling, Gavin P., et al.
Publicado: (2023)

Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab
por: Li, Fanfan, et al.
Publicado: (2022)

HER2-low metastases of HER2-negative primary tumors: a single institution analysis of intertumoral and internodal heterogeneity in node-positive breast cancer
por: Pellas, Ulrika, et al.
Publicado: (2023)

Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients
por: Wang, Jinhao, et al.
Publicado: (2023)

Immunotherapy for HER-2 positive breast cancer
por: Yang, Tingting, et al.
Publicado: (2023)

The Potential Use of DCE-MRI Texture Analysis to Predict HER2 2+ Status
por: Jiang, Zejun, et al.
Publicado: (2019)

A nomogram to predict HER2 status in breast cancer patients with HER2-borderline disease as determined via immunohistochemistry
por: Guo, Qianqian, et al.
Publicado: (2017)

Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer
por: Xie, Yifan, et al.
Publicado: (2021)

Breast Cancer With a HER2 IHC2+ and FISH HER2/CEP17 Ratio ≥2.0 and an Average HER2 Gene Copy Number <4.0 per Tumor Cell: HER2 mRNA Overexpression Is a Rare Event
por: Liu, Yuanyuan, et al.
Publicado: (2020)

Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers
por: Ede, Nicholas J., et al.
Publicado: (2022)

Predicting HER2 Status in Breast Cancer on Ultrasound Images Using Deep Learning Method
por: Xu, Zilong, et al.
Publicado: (2022)

Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
por: Laidi, Fatna, et al.
Publicado: (2014)

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification
por: Meedendorp, Arenda D., et al.
Publicado: (2018)

Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor()
por: Beije, Nick, et al.
Publicado: (2016)

The Prognosis of Single Hormone Receptor-Positive Breast Cancer Stratified by HER2 Status
por: Zhao, Hengqiang, et al.
Publicado: (2021)

The Conundrum of Adjuvant HER2 Treatment Options
por: Bulbul, Ajaz, et al.
Publicado: (2018)

Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer
por: Gerratana, Lorenzo, et al.
Publicado: (2020)

Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancer
por: Han, Yanjie, et al.
Publicado: (2023)

Texture Analysis of Breast DCE-MRI Based on Intratumoral Subregions for Predicting HER2 2+ Status
por: Lu, Hecheng, et al.
Publicado: (2020)

A Novel Small Molecular Antibody, HER2-Nanobody, Inhibits Tumor Proliferation in HER2-Positive Breast Cancer Cells In Vitro and In Vivo
por: Yan, Yan, et al.
Publicado: (2021)

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
por: Wang, Wei, et al.
Publicado: (2022)

Challenges and future of HER2-positive gastric cancer therapy
por: Ma, Chenzhe, et al.
Publicado: (2023)

Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report
por: Huang, Le-Tian, et al.
Publicado: (2019)

Quantitative Parameters of Diffusion Spectrum Imaging: HER2 Status Prediction in Patients With Breast Cancer
por: Mao, Chunping, et al.
Publicado: (2022)

HER2 status in recurrent/metastatic androgen receptor overexpressing salivary gland carcinoma patients
por: Cavalieri, Stefano, et al.
Publicado: (2023)

Evolution and clinical significance of HER2-low status after neoadjuvant therapy for breast cancer
por: Shang, Jiuyan, et al.
Publicado: (2023)

Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies
por: Bergado-Báez, Gretchen, et al.
Publicado: (2022)

Preoperative Systemic Therapy Versus Upfront Surgery in HER2-Positive Breast Cancer in the Real World
por: Yu, Xingfei, et al.
Publicado: (2021)

HER2 exon 27 mutations predict worse survival of breast cancer patients, especially in HER2‐negative patients
por: Si, Pilei, et al.
Publicado: (2017)

Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients
por: Zhang, Shaohua, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0s74makuf7h8n0vcvnhl66p7ai